Updates are available Correction dated 2024-06-24
Click to view Correction: https://doi.org/10.1007/s10103-024-04036-9
-
Authors
Vatandoust, Dorsa https://orcid.org/0000-0002-7456-3215
Ahmadi, Houssein https://orcid.org/0000-0002-6300-4143
Amini, Abdollah https://orcid.org/0000-0002-9408-3200
Mostafavinia, Atarodalsadat https://orcid.org/0000-0003-2270-5637
Fathabady, Fatemeh Fadaei https://orcid.org/0000-0002-8426-3646
Moradi, Ali https://orcid.org/0000-0003-4169-0354
Fridoni, Mohammadjavad https://orcid.org/0000-0001-8876-7705
Hamblin, Michael R https://orcid.org/0000-0001-6431-4605
Ebrahimpour-Malekshah, Roohollah
Chien, Sufan https://orcid.org/0000-0002-1067-4178
Bayat, Mohammad https://orcid.org/0000-0001-5214-4223
-
Funding
Funding for this research was provided by:
NIH (R44DK133065)
NIH (R44DK105692)
- License Information
-
More Information
Article History
Received: 23 November 2023
Accepted: 23 February 2024
First Online: 5 March 2024
Change Date: 24 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10103-024-04036-9
Declarations
:
: This work (file no: IR.SBMU.MSP.REC.1400. 693) was permitted by the IRB at the School of medicine at Shahid Beheshti University of Medical Sciences.
: Dr. Michael R Hamblin states the following possible conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; JOOVV Inc, Minneapolis-St. Paul MN; Sunlighten, Kansas City, MO; Consulting; USHIO Corp, Japan; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany; Klox Asia, Guangzhou, China. Stockholding: Niraxx Light Therapeutics, Inc, Irvine CA; JelikaLite Corp, New York NY. The other authors declare no conflicts of interest.
